Nanox Announces Live Demonstration of its Nanox.ARC System at Radiology
Society of North America (RSNA) 2020
NEVE ILAN, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD
(NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging
technology company, is pleased to announce today that it will demonstrate its
novel technology (Nanox.SOURCE) and medical imaging system (Nanox.ARC) at RSNA
2020, which is being held November 29-December 5 in Chicago.
The demonstration will include a technology section elaborating on Nanox’s
first commercial-grade digital x-ray source followed by a live demonstration
of the Nanox.ARC in a range of 2D and 3D medical imaging procedures.
The demonstration will be led by Mr. Ran Poliakine, Chairman and Chief
Executive Officer of Nanox, and will be live streamed globally. It will
include a professional radiology Q&A session followed by lectures and
presentations of clinical applications of the Nanox.ARC medical imaging system
by well-known radiologists and Company distribution partners.
Mr. Poliakine stated: “We are pleased to invite everyone to witness first-hand
our technology and the Nanox.ARC at the RSNA. We have an ambitious goal of
making medical imaging widely available on a global basis to promote
preventive healthcare through early detection. Two-thirds of the world’s
population currently have no access to medical imaging, and we aim to improve
this statistic. We look forward to this demonstration which will allow people
to see the depth and validity of our technology.”
About Nanox:
Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli
corporation that is developing a commercial-grade digital X-ray source
designed to be used in real-world medical imaging applications. Nanox believes
that its novel technology could significantly reduce the costs of medical
imaging systems and plans to seek collaborations with world-leading healthcare
organizations and companies to provide affordable, early detection imaging
service for all. For more information, please visit www.nanox.vision.
Forward-Looking Statements:
This press release may contain forward-looking statements that are subject to
risks and uncertainties. All statements that are not historical facts
contained in this press release are forward-looking statements. Such
statements include, but are not limited to, any statements relating to the
initiation, timing, progress and results of Nanox's research and development,
manufacturing and commercialization activities with respect to its X-ray
source technology and the Nanox.ARC. In some cases, you can identify
forward-looking statements by terminology such as “can,” “might,” “believe,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,”
“should,” “could,” “expect,” “predict,” “potential,” or the negative of these
terms or other similar expressions. Forward-looking statements are based on
information Nanox has when those statements are made or management's good
faith belief as of that time with respect to future events, and are subject to
risks and uncertainties that could cause actual performance or results to
differ materially from those expressed in or suggested by the forward-looking
statements. Factors that could cause actual results to differ materially from
those currently anticipated include: risks related to business interruptions
resulting from the COVID-19 pandemic or similar public health crises could
cause a disruption of the development, deployment or regulatory clearance of
the Nanox System and adversely impact our business; Nanox's ability to
successfully demonstrate the feasibility of its technology for commercial
applications; Nanox's expectations regarding the necessity of, timing of
filing for, and receipt and maintenance of, regulatory clearances or approvals
regarding its X-ray source technology and the Nanox.ARC from regulatory
agencies worldwide and its ongoing compliance with applicable quality
standards and regulatory requirements; Nanox's ability to enter into and
maintain commercially reasonable arrangements with third-party manufacturers
and suppliers to manufacture the Nanox.ARC; the market acceptance of the
Nanox.ARC and the proposed pay-per-scan business model; Nanox's expectations
regarding collaborations with third-parties and their potential benefits; and
Nanox's ability to conduct business globally, among others. Except as required
by law, Nanox undertakes no obligation to update publicly any forward-looking
statements after the date of this press release to conform these statements to
actual results or to changes in Nanox's expectations.
Contact:
Itzhak Maayan
Nanox Imaging
[email protected]
Bob Yedid
LifeSci Advisors
646-597-6989
[email protected]
NNOX.png
Source Article
